Last updated: November 17, 2026
SUSTOL, Heron Therapeutics’ extended-release granisetron injection, was FDA-approved in 2016 for prevention of acute and delayed chemotherapy-induced nausea and vomiting. Its commercial opportunity was limited by competition from inexpensive generic antiemetics, slow hospital adoption, manufacturing constraints, and Heron’s later decision to discontinue commercial operations. SUSTOL generated modest revenue compared with Heron’s CINVANTI and ZYNRELEF franchises and is no longer a meaningful growth driver.
What is SUSTOL and how does it work?
SUSTOL is a subcutaneous extended-release formulation of granisetron, a selective 5-HT3 receptor antagonist. It was designed to provide antiemetic coverage for both acute and delayed nausea and vomiting after moderately emetogenic chemotherapy.
| Attribute |
SUSTOL |
| Active ingredient |
Granisetron |
| Dosage form |
Extended-release subcutaneous injection |
| FDA application |
NDA 208239 |
| FDA approval |
November 14, 2016 |
| Developer and commercial sponsor |
Heron Therapeutics |
| Primary indication |
Acute and delayed chemotherapy-induced nausea and vomiting |
| Target setting |
Oncology clinics and outpatient infusion centers |
| Principal alternatives |
Generic ondansetron, generic granisetron, palonosetron, rolapitant, aprepitant, fosaprepitant, CINVANTI |
| Current commercial position |
Commercially discontinued by Heron |
The product’s differentiated value proposition was administration convenience. Conventional granisetron and ondansetron generally require more frequent dosing or are administered as part of a multi-drug antiemetic regimen. SUSTOL attempted to convert that convenience into a premium oncology-supportive-care product.
When did SUSTOL receive FDA approval and lose commercial momentum?
The FDA approved SUSTOL in 2016. Heron launched the product in 2017, initially targeting oncology practices that wanted a long-acting injectable option for chemotherapy-induced nausea and vomiting.
Commercial uptake remained limited. The product competed against established generic products with low acquisition costs and against branded or protected agents such as palonosetron and aprepitant-based regimens. Payers and infusion centers also had limited incentives to replace familiar generic protocols.
Heron subsequently reduced or discontinued SUSTOL commercial activity after manufacturing and supply issues affected the product. Heron’s public filings indicate that the company stopped commercial operations for SUSTOL and focused resources on CINVANTI and ZYNRELEF. The product therefore moved from a marketed growth asset to a non-core or discontinued product.
SUSTOL commercial timeline
| Date |
Event |
| 2016 |
FDA approval of SUSTOL under NDA 208239 |
| 2017 |
Commercial launch by Heron Therapeutics |
| 2018-2021 |
Limited commercial expansion in chemotherapy-induced nausea and vomiting |
| 2022-2023 |
Declining strategic importance as Heron prioritized CINVANTI and ZYNRELEF |
| 2023 |
Heron reported discontinuation of SUSTOL commercial operations |
| 2024 onward |
No material SUSTOL growth contribution reported by Heron |
The commercial discontinuation materially reduces the relevance of patent life, Orange Book timing, and potential generic entry. A generic competitor would face a smaller addressable market if the branded product is no longer actively supplied.
How much revenue did SUSTOL generate?
SUSTOL revenue was modest and volatile. Heron’s annual reports show that the product never approached the scale of the company’s leading products. Revenue was affected by oncology treatment volumes, formulary access, payer reimbursement, stocking behavior, manufacturing availability, and the company’s decision to redirect commercial resources.
Public filings report SUSTOL revenue within Heron’s product-sales disclosures. The reported pattern was a short period of commercialization followed by a decline as the company exited the product.
| Period |
Financial trajectory |
Main interpretation |
| 2017 |
Early launch revenue |
Initial market-building phase |
| 2018-2019 |
Low tens of millions of dollars annually |
Product gained limited adoption but remained commercially small |
| 2020-2021 |
Volatile revenue |
COVID-19 disruption and oncology-treatment volume changes affected demand |
| 2022 |
Declining strategic contribution |
Heron emphasized CINVANTI and ZYNRELEF |
| 2023 |
Material reduction or cessation |
Commercial discontinuation eliminated SUSTOL as a growth driver |
SUSTOL was not the core source of Heron’s valuation. Heron’s financial trajectory increasingly depended on CINVANTI, an injectable aprepitant product, and ZYNRELEF, a long-acting local analgesic. SUSTOL’s limited sales meant that its discontinuation had less impact on enterprise value than changes in the performance of those products.
What drove SUSTOL’s weak financial performance?
Four factors constrained the product:
- Generic price competition. Granisetron and ondansetron were available in low-cost injectable and oral forms.
- Limited clinical differentiation. SUSTOL improved dosing convenience but did not establish a broad efficacy advantage over standard antiemetic combinations.
- Oncology purchasing control. Hospitals and infusion centers often use protocol-driven formularies with strict cost controls.
- Manufacturing and supply execution. Heron’s public disclosures identified manufacturing and commercial constraints that impaired product continuity.
The product therefore had a premium-pricing model without a sufficiently strong reimbursement or clinical basis to support broad adoption.
What patents protect SUSTOL?
SUSTOL’s intellectual-property position centered on its extended-release granisetron formulation, injectable delivery system, manufacturing process, and related pharmaceutical compositions. The product was not protected only by the active ingredient, because granisetron itself was an older and widely available molecule.
The relevant patent categories were:
| Patent category |
Commercial purpose |
| Extended-release formulation patents |
Protect sustained granisetron release after subcutaneous administration |
| Microsphere or depot technology patents |
Protect the physical drug-delivery platform |
| Composition-of-matter and excipient claims |
Protect particular polymer, solvent, or excipient combinations |
| Manufacturing patents |
Protect preparation of the injectable depot formulation |
| Method-of-use patents |
Protect administration for chemotherapy-induced nausea and vomiting |
The FDA Orange Book is the controlling source for patents listed against NDA 208239. Orange Book listings can change over time through patent expiration, delisting, corrections, and regulatory updates. A patent’s presence in the Orange Book does not itself establish that every patent claim would survive validity or infringement challenges.
How strong was the SUSTOL patent estate?
The estate was stronger against direct substitution with the same extended-release injectable design than against ordinary granisetron or ondansetron products. A competitor seeking to copy SUSTOL’s depot formulation would face more technical and patent risk than a company selling conventional granisetron.
The estate was weaker as a commercial barrier because:
- Granisetron was already generic.
- Competitors could use different delivery technologies.
- The indication was supported by multiple established antiemetic therapies.
- The product’s commercial discontinuation reduced the value of enforcing formulation rights.
- Manufacturing reproducibility, rather than patent protection alone, was a significant barrier to entry.
What is the Orange Book status of SUSTOL?
SUSTOL was approved under FDA NDA 208239. The Orange Book is the relevant FDA database for determining whether listed patents and regulatory exclusivities are associated with the NDA.
SUSTOL did not receive a new chemical entity exclusivity period because granisetron had already been approved. Its regulatory protection therefore depended on the approved formulation, listed patents, and any applicable clinical or pediatric exclusivity. The product’s practical exclusivity was narrower than that of a new molecular entity.
| Regulatory protection |
SUSTOL position |
| New chemical entity exclusivity |
Not applicable |
| New clinical investigation exclusivity |
Potentially relevant only if FDA granted applicable protection |
| Pediatric exclusivity |
No material public commercial significance identified |
| Orange Book patents |
Relevant to an ANDA applicant’s certification strategy |
| Regulatory exclusivity after commercial discontinuation |
Limited practical value |
When does SUSTOL lose exclusivity?
SUSTOL’s active-ingredient exclusivity had already expired before FDA approval because granisetron was an established compound. The remaining protection depended on formulation and delivery patents rather than the granisetron molecule.
The practical loss of exclusivity occurred earlier than a formal patent expiration because SUSTOL ceased to be a significant commercial product. A patent may remain enforceable after a product is discontinued, but the economic value of that patent falls sharply when branded supply is unavailable and the addressable market is small.
A definitive generic-entry date cannot be determined from the FDA approval date alone. The relevant date would depend on:
- Each Orange Book-listed patent;
- Patent expiration and terminal-disclaimer calculations;
- Any patent-term extension;
- Paragraph IV certification by an ANDA applicant;
- Litigation within the statutory 45-day period;
- FDA approval timing;
- Whether Heron or an assignee continued to enforce the rights.
Were there Paragraph IV challenges to SUSTOL?
No major publicly reported Paragraph IV challenge or federal patent case materially affecting SUSTOL commercialization is identified in Heron’s principal public disclosures and the FDA materials associated with the product.
That does not establish that no ANDA certification was ever submitted. FDA generally does not disclose the full contents of every ANDA, and Paragraph IV litigation may involve limited public reporting. The commercial record indicates that SUSTOL’s principal problem was market execution and product discontinuation rather than a highly visible generic patent battle.
What generic launch risks exist for SUSTOL?
A generic entrant would face two separate questions:
- Could it obtain FDA approval through an ANDA or another abbreviated pathway?
- Would a commercially viable market remain after SUSTOL’s discontinuation?
Potential launch paths include:
- An ANDA referencing SUSTOL’s safety and efficacy data;
- A formulation that uses a different extended-release technology;
- A conventional granisetron product competing for the same treatment protocol;
- A hospital-administered antiemetic product that avoids SUSTOL’s formulation patents.
The highest technical risk would involve reproducing SUSTOL’s extended-release profile, injectable depot characteristics, stability, and manufacturing process. The highest commercial risk would be inadequate demand.
Which companies compete with SUSTOL?
SUSTOL competed in a crowded antiemetic market rather than in a narrow single-product category.
| Competitor |
Product or class |
Competitive relevance |
| Generic manufacturers |
Ondansetron |
Low-cost standard antiemetic |
| Generic manufacturers |
Granisetron |
Direct active-ingredient competition |
| Helsinn and partners |
Aloxi, palonosetron |
Long-acting 5-HT3 antagonist |
| Heron Therapeutics |
CINVANTI |
Injectable aprepitant used in chemotherapy regimens |
| Merck |
Emend and related products |
NK1 antagonist-based antiemetic therapy |
| Generic manufacturers |
Fosaprepitant and aprepitant |
Established alternatives |
| Eisai |
Rolapitant |
Long-acting NK1 antagonist, subject to market and supply changes |
CINVANTI was strategically more important to Heron because it addressed a larger and better-established antiemetic treatment component. SUSTOL’s differentiation depended primarily on dosing convenience, while CINVANTI participated in guideline-based combination regimens involving an NK1 antagonist.
How does SUSTOL compare with CINVANTI and ZYNRELEF?
| Metric |
SUSTOL |
CINVANTI |
ZYNRELEF |
| Therapeutic area |
Chemotherapy-induced nausea and vomiting |
Chemotherapy-induced nausea and vomiting |
Postsurgical pain |
| Active ingredient or platform |
Extended-release granisetron |
Injectable aprepitant |
Bupivacaine and meloxicam |
| Market status |
Commercially discontinued |
Core Heron product |
Core Heron growth product |
| Main differentiation |
Extended dosing interval |
Intravenous formulation and regimen integration |
Long-acting local pain control |
| Generic pressure |
High |
Moderate to high |
Lower in the near term because of formulation and combination-product barriers |
| Revenue importance to Heron |
Low |
Material |
Material growth driver |
| Key risk |
Limited adoption and supply execution |
Hospital formulary access and competition |
Payer adoption, surgery volumes, and product differentiation |
SUSTOL was the weakest of the three assets from a portfolio perspective. CINVANTI had clearer alignment with established antiemetic protocols. ZYNRELEF had a larger strategic opportunity because its combination formulation targeted opioid reduction and postsurgical pain management.
What manufacturing and IP barriers affected SUSTOL?
SUSTOL required reproducible production of an extended-release injectable formulation. That creates technical requirements beyond those associated with conventional granisetron injections:
- Controlled particle or depot characteristics;
- Consistent drug loading;
- Release-rate reproducibility;
- Sterility and injectable-product controls;
- Stability over the labeled shelf life;
- Reliable scale-up at a contract manufacturing facility.
These requirements can create meaningful entry barriers even when the active ingredient is generic. They also increase operational risk for the sponsor. A manufacturing interruption can eliminate sales more quickly than a patent challenge when the product has limited market share and few redundant suppliers.
SUSTOL’s manufacturing complexity was therefore both a competitive advantage and a commercial liability.
What litigation and settlement agreements affected SUSTOL?
No major publicly disclosed patent settlement involving SUSTOL has materially shaped the product’s commercial history. Heron’s disclosed litigation and legal-risk profile has been more closely associated with its broader product portfolio, including other branded products and commercial disputes.
The absence of a major settlement is consistent with the product’s limited sales and declining commercial relevance. A generic manufacturer would have had less incentive to litigate aggressively against a small or discontinued market.
What is SUSTOL’s geographic coverage?
SUSTOL’s principal regulatory and commercial value was in the United States. Heron’s public strategy focused on the U.S. oncology market rather than building a large international franchise.
International expansion would have required separate regulatory approvals, local reimbursement, oncology protocol adoption, and supply infrastructure. Those requirements were difficult to justify for a product with limited U.S. penetration and strong generic competition.
| Region |
Commercial position |
| United States |
FDA-approved and commercially launched |
| Europe |
No comparable major commercial position publicly established |
| Asia-Pacific |
No material Heron-led commercial footprint publicly established |
| Other markets |
Limited strategic relevance |
What is the investment outlook for SUSTOL?
SUSTOL has little standalone investment value. Its key financial characteristics are:
- Low historical revenue relative to Heron’s leading products;
- No meaningful current growth trajectory;
- Limited remaining commercial leverage;
- High substitution risk from generic antiemetics;
- Reduced value from formulation patents after commercial discontinuation;
- Potential residual value only through intellectual-property licensing, asset sale, or technical know-how.
For investors and licensors, SUSTOL should be treated as a discontinued or non-core asset rather than a growth product. Any residual value would depend on a third party’s ability to restart manufacturing, secure reimbursement, and demonstrate a sufficiently differentiated clinical or economic proposition.
Key Takeaways
- SUSTOL is an extended-release subcutaneous granisetron product approved by the FDA in 2016.
- Its commercial opportunity was constrained by generic ondansetron and granisetron, established antiemetic protocols, and limited payer differentiation.
- Revenue remained modest and did not approach the scale of Heron’s CINVANTI or ZYNRELEF businesses.
- Heron discontinued SUSTOL commercial operations after manufacturing and strategic execution problems.
- The product’s patent value centered on formulation, depot-delivery, manufacturing, and method-of-use claims rather than the granisetron molecule.
- No major publicly reported Paragraph IV litigation or patent settlement materially affected SUSTOL’s market history.
- Generic entry risk is technically meaningful for a copy of the depot formulation but commercially limited because the branded product is no longer a major active franchise.
- SUSTOL has limited standalone licensing, investment, or revenue potential.
FAQs
Is SUSTOL still available in the United States?
Heron discontinued commercial operations for SUSTOL. Current availability should not be assumed from the product’s historical FDA approval.
Is SUSTOL the same as generic granisetron?
No. SUSTOL is an extended-release subcutaneous formulation of granisetron. Generic granisetron products generally use different dosage forms, release profiles, or administration schedules.
Could a generic company relaunch SUSTOL?
A company could pursue an abbreviated approval strategy or develop a different extended-release granisetron product, but it would need to address formulation patents, product-specific FDA requirements, manufacturing complexity, and limited market demand.
Was SUSTOL a blockbuster drug?
No. SUSTOL generated modest revenue and remained a minor product within Heron’s portfolio. It did not reach blockbuster status.
Which Heron product replaced SUSTOL strategically?
CINVANTI became the more important oncology-supportive-care product in Heron’s portfolio. ZYNRELEF became the company’s principal growth asset outside antiemetics.
References
-
U.S. Food and Drug Administration. (2016). FDA approves Sustol for prevention of chemotherapy-induced nausea and vomiting. https://www.fda.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Sustol, NDA 208239. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Heron Therapeutics, Inc. (2018-2023). Annual reports on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1589168
-
Heron Therapeutics, Inc. (2023). Reports on commercial portfolio priorities and SUSTOL operations. https://ir.herontx.com/
-
Heron Therapeutics, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1589168